Podcast with Gaurang Telang
Audio will be available soon!
About this Podcast:
An in-depth conversation examining why scientific talent migrates across borders and what system reliability, quality culture, and translational infrastructure have to do with it. This episode explores how cell and gene therapy innovation depends not only on biology, but on structured ecosystems that allow science to move predictably from bench to patient.
About the guest:
His day-to-day work is bench-intensive and process-driven, focused on engineering, measuring, and validating T-cell products with an emphasis on reproducibility, documentation, and clinical translation. He works in a pre-GMP translational environment that bridges basic immunology research with downstream clinical and manufacturing requirements.
Episode overview:
What slows cell and gene therapy, biology or systems?
In Episode 4 of The Cure Circle, host Dr. Smita Karpate speaks with Gaurang Telang, a translational T-cell immunotherapy researcher at the Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany, whose work bridges bench-level CAR-T research and GMP-aligned translational science.
This episode asks a question many avoid but everyone in Indian science feels:
Why do talented researchers leave India and what is the real cost of that loss?
Gaurang did not leave because of ambition alone. He left because, over time, his scientific progress became limited not by biology, but by system friction – procurement delays, unreliable infrastructure, unclear career paths, and a constant firefighting mindset that erodes creativity.
Now working in a highly structured translational ecosystem in Germany, he offers a rare, honest comparison between resource-constrained innovation and process-driven science, and explains why talent moves toward environments where the bottleneck is biology, not logistics.
This is not a story about brain drain.
It is a diagnosis of system reliability, quality culture, and legible careers.
In this episode, Dr. Karpate and Gaurang Telang discuss:
- Why researchers don’t “choose to leave”, they respond to accumulated system friction
- How procurement delays, approvals, and unreliable supply chains silently destroy productivity
- Why scientific creativity requires predictability, calm, and psychological safety
- The hidden cost of constant firefighting in Indian research environments
- Germany’s unique position between pure academia and industry-grade translation
- What translational institutes get right: documentation, reproducibility, GMP-aligned thinking
- Why cell & gene therapy success depends on boring fundamentals, not heroics
- The myth of patriotism as a substitute for functioning incentives
- Why India does not have a talent problem, but a system reliability problem
- The “Tesla moment” India needs in biotech: a few platform companies, not hundreds of startups
- Why quality shortcuts in CGT will backfire and set ecosystems back years
- What researchers actually need to return: healthcare security, legible careers, dignity of work
It reframes the conversation from “Why don’t people stay?”
to “What kind of system deserves them?”
Episode 4 reinforces The Cure Circle’s mission:
to examine not just scientific possibility, but the structures required to turn science into patient impact.
